Real‐world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive‐disease small‐cell lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4938
Abstract: The aim of this study was to assess the effectiveness and tolerability of atezolizumab plus carboplatin and etoposide combination chemotherapy in elderly patients with extensive‐disease (ED) small‐cell lung cancer (SCLC). read more here.
Keywords: elderly patients; carboplatin etoposide; plus carboplatin; patients extensive ... See more keywords
Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-019-03962-8
Abstract: Triple-negative breast cancer (TNBC) has a poor prognosis because of limited treatment options. The combination of a poly ADP ribose polymerase (PARP) inhibitor with a DNA-damaging agent has shown promise in treating TNBC; however, not… read more here.
Keywords: combination; plus carboplatin; dasatinib; veliparib ... See more keywords
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Oncology"
DOI: 10.1093/annonc/mdy201
Abstract: Abstract Background Metastatic triple-negative breast cancer (mTNBC) has a poor prognosis and aggressive clinical course. tnAcity evaluated the efficacy and safety of first-line nab-paclitaxel plus carboplatin (nab-P/C), nab-paclitaxel plus gemcitabine (nab-P/G), and gemcitabine plus carboplatin… read more here.
Keywords: nab paclitaxel; plus carboplatin; gemcitabine; first line ... See more keywords
Efficacy, safety and prognostic factors of camrelizumab plus carboplatin and pemetrexed chemotherapy in advanced lung adenocarcinoma patients
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.13664
Abstract: Camrelizumab is a recently developed PD‐1 inhibitor in China applied in treating different cancers including lung cancer. This study is designed to evaluate the efficacy, safety and prognostic factors for camrelizumab plus carboplatin and pemetrexed… read more here.
Keywords: prognostic factors; safety prognostic; camrelizumab plus; plus carboplatin ... See more keywords
Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study
Sign Up to like & getrecommendations! Published in 2020 at "ESMO Open"
DOI: 10.1136/esmoopen-2020-000672
Abstract: Background Glioblastoma relapse is associated with activation of phosphatidylinositol 3-kinase (PI3K) signalling pathway. In preclinical studies, the pan-PI3K inhibitor buparlisib showed antitumour activity in glioma models. Methods This was a two-part, multicentre, phase Ib/II study… read more here.
Keywords: phase; buparlisib; plus carboplatin; carboplatin lomustine ... See more keywords
Real-world outcomes of pembrolizumab plus carboplatin plus paclitaxel or nab-paclitaxel in non-small cell lung cancer (NSCLC).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e21717
Abstract: e21717Background: Pem+carbo+pac or nab-pac are approved first-line (1L) treatments for metastatic squamous NSCLC since 10/30/2018. Difference in real-world outcomes of these triplet combinations ar... read more here.
Keywords: outcomes pembrolizumab; real world; plus carboplatin; world outcomes ... See more keywords
Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting
Sign Up to like & getrecommendations! Published in 2017 at "Lung Cancer: Targets and Therapy"
DOI: 10.2147/lctt.s139647
Abstract: Introduction Real-world comparative effectiveness, safety, and supportive care use of nab-paclitaxel plus carboplatin vs gemcitabine plus platinum were analyzed in patients with advanced or metastatic squamous cell non-small cell lung cancer (NSCLC). Materials and methods… read more here.
Keywords: gemcitabine plus; nab paclitaxel; paclitaxel plus; plus carboplatin ... See more keywords
Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1080729
Abstract: Background There are no established predictive biomarkers for the effectiveness of first-line atezolizumab plus carboplatin and etoposide therapy in patients with small-cell lung cancer (SCLC). Therefore, the current study aimed to investigate whether the Glasgow… read more here.
Keywords: carboplatin etoposide; first line; plus carboplatin; line atezolizumab ... See more keywords